All In Biotech

Drug Trial Radar · NCT07402330

Pharmacokinetic Study of DA-020

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 16, 2026

Primary completion

Oct 19, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Applied Biology, Inc.Industry
Sponsor type
Industry
Collaborators
Daniel Alain, Inc.; Follea International Limited
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Pharmacokinetic Study of DA-020

Conditions

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Interventions

  • DA-020 (0.1%)Drug

    DA-020 (0.1%)

  • DA-020 (0.2%)Drug

    DA-020 (0.2%)

  • DA-020 (0.5%)Drug

    DA-020 (0.5%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of DA-020 in SerumTime frame: Hours [0, 1, 2, 4, 8, 12, 24]

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Samel

    Manaus, Brazil

  • University of Rome ("G. Marconi")

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.